Please assess the completion status of the following clinical trial:

Trial Title: RESIPI for Reducing Perioperative Major Adverse Cardiac Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Revised Cardiac Risk Index greater than or equal to 1, history of diastolic dysfunction, or age greater than 55 years.~* Surgery type: Major Abdominal Oncologic Surgery~* Planned surgery length greater than or equal to 90 minutes with planned in-patient stay of at least 2 days~Exclusion Criteria:~* Patients who are unstable by current American Heart Association/American College of Cardiology Clinical Practice Guidelines~* Patients with Chronic Kidney Disease Stage IV or V~* Urgent/emergent surgical interventions (e.g. Level 1 or 2 by VUMC VOR definitions)~* No signs of ischemia, congestive heart failure, or volume overload: Creatinine Clearance greater than 30

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard intraoperative care- no interventions (Type: ACTIVE_COMPARATOR): Standard intraoperative hemodynamic monitoring and treatment at Vanderbilt University Medical Center - No study interventions
- RESIPI (Type: EXPERIMENTAL): Intraoperative implementation of RESIPI management strategy, a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical).

Based on this trial design, predict the completion outcome and termination type (if applicable).